ReviewThe pharmacogenomics journal
Overview of the pharmacogenetics of asthma treatment.
Review in The pharmacogenomics journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 95 citations in OpenAlex.
- Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children.Drug design, development and therapy · 2019Trial
- Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program.The Journal of allergy and clinical immunology · 2008Trial
- Asthma and Corticosteroid Responses in Childhood and Adult Asthma.Clinics in chest medicine · 2019Review
- Association of genetic variants with level of asthma control in the Arab population.Journal of asthma and allergy · 2019Article
- Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.The Journal of international medical research · 2017Review
- The links between chronic obstructive pulmonary disease and comorbid depressive symptoms: role of IL-2 and IFN-γ.Clinical and experimental medicine · 2016Article
- The Therapeutic Potential of Targeting Cytokine Alarmins to Treat Allergic Airway Inflammation.Frontiers in physiology · 2016Review
- Beta2 adrenergic receptor (ADRβ2) haplotype pair (2/4) is associated with severe asthma.PloS one · 2014Article
- Article
- Integrative systems biology approaches in asthma pharmacogenomics.Pharmacogenomics · 2012Review
- The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).Transactions of the American Ophthalmological Society · 2011Article
- Article
- Update on the role of genetics in the onset of age-related macular degeneration.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
- The role of pharmacogenomics in improving the management of asthma.The Journal of allergy and clinical immunology · 2010Review
- Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response.Pharmacogenetics and genomics · 2009Article
- Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.The American journal of drug and alcohol abuse · 2009Review
- ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts.American journal of respiratory and critical care medicine · 2008Article
- Ketotifen controlled release from cellulose acetate propionate and cellulose acetate butyrate membranes.Journal of materials science. Materials in medicine · 2008Article
- ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study.PloS one · 2007Article
- The pharmacogenetics research network: from SNP discovery to clinical drug response.Clinical pharmacology and therapeutics · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Asthma affects approximately 300 million individuals worldwide. Medications comprise a substantial portion of asthma expenditures. Despite the availability of three primary therapeutic classes of medications, there are a significant number of nonresponders to therapy. Available data, as well as previous pharmacogenetic studies, suggest that genetics may contribute as much as 60-80% to the interindividual variability in treatment response. In this methodologic review, after providing a broad overview of the asthma pharmacogenetics literature to date, we describe the application of a novel family-based screening algorithm to the analysis of pharmacogenetic data and highlight our approach to identifying and verifying loci influencing asthma treatment response. This approach seeks to address issues related to multiple comparisons, statistical power, population stratification, and failure to replicate from which previous population-based or case-control pharmacogenetic association studies may suffer. Identification of such replicable loci is the next step towards the goal of 'individualized therapy' for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.